Academic Interest of Allergists in Atopic Dermatitis before and after Approval of Systemic Immunomodulators

Atopic dermatitis (AD) is a common inflammatory skin disease that has traditionally been managed by dermatologists. In March 2017, the United States Food and Drugs Administration (FDA) approved the first biologic, dupilumab, for the treatment of moderate-to-severe AD.1 Dupilumab is a monoclonal antibody that targets IL-4 and IL-13, which are the leading causes of allergic inflammation in various conditions including AD, asthma, eosinophilic esophagitis, and chronic rhinosinusitis with nasal polyps.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Tags: Letters Source Type: research